Pro-Pharmaceuticals' Executives Contribute to Definitive Book on Galectins
June 25 2008 - 7:00AM
Business Wire
Pro-Pharmaceuticals, Inc. (Amex: PRW), a Company developing
proprietary carbohydrate-based therapeutic compounds to treat
cancer and fibrosis, today announced two of its executives and a
member of its Scientific Advisory Board edited a new book
�Galectins� and authored one of the chapters. The book offers a
comprehensive guide to the current understanding of galectins,
their promising potential in drug design and the role galectins
play in tumor growth, cancer, angiogenesis, resistance to
chemotherapy, and the initiation and proliferation of organ
fibrosis. �This is the first book focusing on galectins and their
biomedical applications. The book is inspired by topics discussed
at the symposium �Galectins: Structures, Functions, and Therapeutic
Targets� sponsored by Pro-Pharmaceuticals as part of the American
Chemical Society�s 234th annual meeting held in 2007,� said Anatole
Klyosov, Ph.D., D.Sc., Chief Scientist, Pro-Pharmaceuticals. �We
believe our expertise in developing carbohydrate-based compounds
that target galectin receptors and offer opportunities for the
advanced treatment of cancer, fibrosis and inflammatory diseases.�
Contributing to the book was Anatole Klyosov; David Platt; Ph.D.,
Chief Executive Officer, Pro-Pharmaceuticals; and Zbigniew J.
Witczak, a member of Pro-Pharmaceuticals Scientific Advisory Board;
Associate Professor at the Nesbitt School of Pharmacy, Wilkes
University, and former chair of the American Chemical Society�s
Division of Carbohydrate Chemistry. The book, published by John
Wiley & Sons, Inc., is a reference on galectins for organic,
medicinal, carbohydrate, and pharmaceutical chemists, biochemists,
molecular and cell biologists, pharmacologists, and cancer
researchers, as well as clinicians and drug developers. The editors
have compiled articles from leading experts on galectins and their
biomedical applications. �Galectins� includes: An overview of early
galectin research An explanation of the nature of galectins A
discussion of the structure and functions of galectins, their
ligand specificity and molecular mechanisms of action, and the
localization of galectins in the cell An exploration of the roles
galectins play in tumor growth and cancer, fibrosis, inflammation,
and immunity The role of galectins in organ fibrosis A discussion
of the effect of galectins on cell migration, angiogenesis, and
chemo-resistance An introduction to new approaches to designing
galectin inhibitors About DAVANAT� DAVANAT�, the Company�s leading
drug candidate, is a proprietary polysaccharide polymer that has a
mechanism of action based on affecting lectins�specific receptors
that bind only to a particular type of carbohydrate. The drug binds
to galectins on tumor cells while selectively avoiding surrounding
healthy tissue. This form of targeted therapy may allow for higher
doses of chemotherapy administration with no increase in toxicity.
Pro-Pharmaceuticals, Inc. � Advancing Drugs Through Glycoscience�
Pro-Pharmaceuticals is a clinical stage pharmaceutical company
engaged in the discovery, development and commercialization of
carbohydrate-based, target therapeutic compounds for advanced
treatment of cancer, liver, microbial and inflammatory diseases.
The Company�s initial focus is the development of carbohydrate
polymers to treat cancer patients. DAVANAT�, the Company�s lead
product candidate, is a polysaccharide polymer that is in Phase II
trials for colorectal and biliary cancer. The Company�s technology
is also being used to develop new chemical entities to treat liver
and kidney fibrosis. The Company is headquartered in Newton, Mass.
Additional information is available at www.pro-pharmaceuticals.com.
FORWARD LOOKING STATEMENTS: Any statements in this news release
about this or future financings, expectations, plans and prospects
for the Company, including without limitation, statements
containing the words "believes," "anticipates," "plans," "expects,"
and similar expressions, constitute forward-looking statements as
defined in the �safe harbor� provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
include statements regarding the expected closing of the private
placement and the anticipated use of proceeds. These
forward-looking statements are based on management�s current
expectations and are subject to a number of factors and
uncertainties, which could cause actual results to differ
materially from those, described in such statements. More
information about those risks and uncertainties is contained in the
Company�s quarterly or annual report, Form 8-K and in the Company�s
other reports filed with the Securities and Exchange Commission.
While the Company anticipates that subsequent events may cause the
Company�s views to change, the Company disclaims any obligation to
update such forward-looking statements. DAVANAT and Advancing Drugs
Through Glycoscience are registered trademarks of
Pro-Pharmaceuticals.
Pro (AMEX:PRW)
Historical Stock Chart
From May 2024 to Jun 2024
Pro (AMEX:PRW)
Historical Stock Chart
From Jun 2023 to Jun 2024